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Venous thromboembolic disease (VTE) is 
a challenging issue in  medicine and for public 
health [1]. VTE is the third most common cardio-
vascular disease after ischemic heart disease and 
ischemic stroke. Approximately half of the patients 
with symptomatic, untreated venous thrombosis 
develop pulmonary embolism, and 10% of cases 
end in sudden death. Death in untreated patients 
is about 30%. However, after initiating treatment, 
it decreases to 3–8% [2]. 
It is particularly challenging to ensure the effec-
tiveness of therapy for patients with VTE. Most pa-
tients, due to comorbidities, take many medications, 
which carries the risk of interactions and other drug-
-related problems. An additional issue is adherence 
to therapy. Patients often do not achieve satisfactory 
health results due to non-adherence. They usually 
take medicine incompletely, inconsistently, or not 
at all. Polypharmacy, inappropriate prescription, and 
drug-related problems increase morbidity and mor-
tality rates and contribute to a large waste of health 
resources. All these situations require effective action 
to improve the quality of patient care [3].
A practical solution for patients is the use of 
various mHealth (mobile health) technologies [4]. 
mHealth is a sub-segment of eHealth and is defined 
as the use of mobile computing and communica-
tion technologies (e.g., mobile phones, wearable 
sensors) for health services and information [5]. 
mHealth includes various methods of interaction 
with the patient — text messages, reminders, but 
also phone applications. 
Many studies are confirming the impact of 
mHealth applications on improving patient out-
comes in different populations and at varying levels 
of healthcare. Applications are particularly important 
for chronically ill patients, including the elderly.
Currently, many mHealth applications are 
available for patients. They support prevention 
diagnostics, patient monitoring, correct use of 
medicines, as well as communication between 
the patient and healthcare staff [5]. mHealth is 
used in patients with diabetes, chronic obstruc-
tive pulmonary disease, or cardiovascular dis-
eases, including hypertension, atrial fibrillation, 
or stroke patients.
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According to available research, there are no 
mobile applications dedicated to patients with VTE 
disease. Given the seriousness of this disease, a de-
cision was made to develop a mobile application for 
patients with VTE disease. “The Patient Access” is 
an application that enables the correct and safe use of 
medicine for people with VTE disease. The application 
displays all drug information in written and graphic 
forms. It also has the function of drug reminders and 
is a compendium of knowledge about VTE disease. 
The application significantly increases the likelihood 
that patients will use medications as directed, which 
is especially important when taking any drug.
To date, the functionality and usability of “The 
Patient Access” mobile application has been verified 
and will support safe drug dosing for people with VTE 
disease.
Testing the application involved assessing the 
usability of a prototype, allowing users to explore 
the application in detail and formulate conclusions 
about both the prototype and the final shape of the 
product. Testing was performed by a target group 
of product users [6]. 
After an application demonstration, each par-
ticipant was asked to answer the questions included 
in the System Usability Scale (SUS). SUS contains 
ten statements related to the subjective assess-
ment of utility. The participant assigns points to 
each statement (according to the Likert 5-point 
scale) assessing the extent to which he agrees 
with the statement. SUS has a good façade validity 
and high reliability (Cronbach’s alpha 0.91) [7, 8].
This study took place at a community phar-
macy in Bialystok, Poland. Participants were 
recruited among persons buying anticoagulants at 
the pharmacy. Study participants had to regularly 
use a smartphone or tablet, which ensured that 
they the basic skills in operating new technologies. 
The age of study participants (> 18 years) was also 
an important criterion. Data were collected from 
March to May 2020.
Sixteen further potential users of the applica-
tion took part in the study. Sample sizes for testing 
the usability of a high-fidelity prototype require only 
5–10 participants to identify 80% of product prob-
lems [9, 10]. For this reason, 16 people participating 
in the study were a sufficient number. The average 
age of the subjects was 64.44 (SD = 15.56). The re-
spondents mainly had a higher education (81.25%). 
After calculating the score according to the SUS 
scale key, the overall assessment of usability of “The 
Patient Access” application was rated at 73.59 points.
Analyzing the average score to each state-
ment in the SUS questionnaire (Table 1), it can be 
assessed that most patients agreed with the state-
ments regarding the ease of use of the application 
and proper integration of functions:
 — “I thought the system was easy to use” (M = 4.35; 
SD = 1.11);
 — “I would imagine that most people would learn 
to use this system very quickly” (M = 4.31; 
SD = 0.87);
 — “I found the various functions in this system 
were well integrated” (M = 4.13; SD = 0.81).
Respondents, disagreed most with statements 
regarding the inconvenience of use, the need to 
help another person when using the application, 
or excessive system complexity:
Table 1. Descriptive statistics of System Usability Scale (SUS) results.
No. of SUS question M Median SD Min Max
1. I think that I would like to use this system frequently 2.81 3 1.11 1 4
2. I found the system unnecessarily complex 1.88 1.5 1.11 1 4
3. I thought the system was easy to use 4.35 5 1.11 2 5
4. I think that I would need the support of a technical person  
to be able to use this system
1.75 1 1.13 1 4
5. I found the various functions in this system were well integrated 4.13 4 0.81 3 5
6. I thought there was too much inconsistency in this system 1.94 2 0.93 1 4
7. I would imagine that most people would learn to use this  
system very quickly
4.31 5 0.87 3 5
8. I found the system very cumbersome to use 1.69 1 1.01 1 4
9. I felt very confident using the system 3.31 3 1.25 1 5
10. I needed to learn a lot of things before I could get going  
 with this system
2.13 2 1.20 1 5
M — average value; SD — standard deviation; Min — minimum value; Max — maximum value
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 — “I found the system very cumbersome to use” 
(M = 1.69; SD = 1.01);
 — “I think that I would need the support of 
a technical person to be able to use this sys-
tem” (M = 1.75; SD = 1.13);
 — “I found the system unnecessarily complex” 
(M = 1.99; SD = 1.11).
This project is innovative because it was the 
first to focus on creating an application support-
ing drug dosage in people with VTE disease. This 
usability and satisfaction research allowed us to 
validate this application before the market launch. 
“The Patient Access” application has been highly 
rated by potential users. Users also indicated those 
features that should be developed in the next phase 
of work on the application.
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